In the United States, over half a million cases of gonorrhoea are diagnosed each year, with rising antibiotic resistance complicating treatment options. For the first time in three decades, researchers have identified a new antibiotic, gepotidacin, which shows promise in addressing this issue. Gonorrhoea, caused by the bacteria Neisseria gonorrhoeae, has increasingly developed resistance to nearly all existing antibiotics, leaving cephalosporins as the last effective treatment option. This situation has been classified as an urgent public health threat by the Centers for Disease Control and Prevention (CDC).
The new treatment, gepotidacin, has recently gained attention following positive results from clinical trials and its recent approval by the FDA for urinary tract infections. Researchers conducted a phase 3 clinical trial involving over 600 participants across six countries, including the U.S. and the U.K. The trial compared gepotidacin, administered orally, to the standard treatment of ceftriaxone (an injection) combined with azithromycin (oral). Results indicated that gepotidacin was equally effective against various strains of gonorrhoea, including those resistant to current therapies.
Gepotidacin operates by inhibiting bacterial DNA replication, thus preventing the bacteria from multiplying. Its oral administration may enhance treatment accessibility, eliminating the need for injections, which could be a significant advantage for patients. The findings were published in The Lancet and presented at the recent European Society of Clinical Microbiology and Infectious Diseases conference. As antibiotic resistance continues to pose challenges in treating gonorrhoea, gepotidacin represents a potential advancement in combating this growing public health concern.